Media
MEDIA & NEWS / Azienda / Giuliani acquires French company Bailleul.
Giuliani acquires French company Bailleul.
The transaction further strengthens the Group’s international expansion strategy.
07
Oct. 2025
Milan, October 7, 2025. Pharmaceutical company Giuliani is strengthening its presence in the hair and skin care sector through the acquisition of Laboratoires Bailleul, a French company specialized in dermatology, trichology, and gynecology.
The transaction, which is part of the Group’s international expansion strategy, is expected to bring turnover to approximately €250 million by 2026.
Founded in Milan in 1889, Giuliani is now a family-owned company with a strong focus on research and the development of products with high scientific value. The acquisition of Bailleul represents a significant step in the company’s international expansion journey, as the French laboratory already operates in many countries.
Laboratoires Bailleul has a well-established pan-European platform and direct operations in France, Italy, Belgium, Portugal, Spain, Germany, Switzerland, Turkey, Greece, and Slovakia. In addition, the company operates two extra-European hubs in Hong Kong and Mexico, as well as a network of qualified international distributors particularly active in China and the Middle East.
“The acquisition of Bailleul strengthens our market position in two core segments of our business — trichology and dermatology — thanks to the strong strategic alignment between the two companies. Our therapeutic focus areas perfectly overlap, while our portfolios and geographical presence are complementary,” stated Gaetano Colabucci, CEO of Giuliani Pharma.
The acquisition is therefore fully aligned with the strategic vision of the Milan-based pharmaceutical company which, as explained by Giammaria Giuliani, is “to build a European leader in the treatment of dermatological and trichological disorders, with strong foundations in Italy and a direct presence in key markets. With Bailleul, we share therapeutic focus, scientific culture, and values. We will combine complementary portfolios, specialist relationship networks, and industrial capabilities to offer even more effective solutions to patients and healthcare professionals. This is a decisive step to accelerate the international growth of our brands and create sustainable value for all stakeholders.”
The acquisition will have a dual impact. On one hand, it will make Giuliani’s offering even more comprehensive across the entire care pathway, from pharmaceuticals and supplements to dermocosmetics. On the other hand, the transaction will support Giuliani’s internationalization strategy, improving results also in terms of profitability.
The transaction was supported by Rothschild & Co as financial advisor and by PwC for due diligence.